SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

TRVI

Trevi Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The improved cash runway into 2028 reduces near-term dilution risk, but value inflection hinges on upcoming Phase 3 trial initiations and data readouts. Monitor enrollment progress in the pivotal IPF cough trials and any protocol finalizations with the FDA.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.69
T+0 close · Mar 17, 2026 · via day close
Latest settled
+25.91%
T+60 · $13.46
Vs SPY
+14.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 18 $10.69entry
  2. T+1 · 8mo ago +0.09%α +0.36% · $10.70
  3. T+5 · 8mo ago +7.02%α +7.73% · $11.44
  4. T+20 · 7mo ago +36.02%α +29.97% · $14.54
  5. T+60 · 5mo ago +25.91%α +14.39% · $13.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Trevi Therapeutics reported fourth quarter and full-year 2025 financial results, highlighted by a reduced net loss and $188.3 million in cash, providing runway into 2028. The company gained FDA alignment on its Phase 3 program for IPF-related chronic cough and plans to initiate pivotal trials in 2026, alongside Phase 2b trials in RCC and non-IPF ILD. Despite no revenue, R&D spending declined while cash position strengthened.

Key Financial Metrics

EPS
$-0.32

Key Facts

  • Ended 2025 with $188.3 million in cash, cash equivalents, and marketable securities, up from $107.6 million in 2024.
  • Net loss for Q4 2025 was $8.3 million vs. $11.4 million in Q4 2024; full-year net loss was $42.8 million vs. $47.9 million in 2024.
  • R&D expenses decreased to $33.5 million in 2025 from $39.4 million in 2024 due to reduced clinical trial activity.
  • Gained FDA alignment on Phase 3 trial design for IPF-related chronic cough; first pivotal trial to start in Q2 2026.
  • Plans to initiate Phase 2b trials in refractory chronic cough (RCC) and non-IPF ILD in 2026.

Financial Impact

Reduced annual net loss by $5.1 million YoY; cash position increased by $80.7 million due to prior financing and interest income.

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Clinical development risk: Phase 3 trials are not yet initiated; FDA may require protocol changes.
  • No revenue-generating products; entirely dependent on clinical success and future funding.
  • Forward-looking statements dominate; actual trial outcomes may differ from management expectations.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257652

Track record

12 reports on TRVI

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
  2. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
  3. Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
  4. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
  5. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
  6. Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
  7. Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
  8. Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
  9. Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
  10. Mar 17, 202634w ago Press Release Mixed 6/10 Viewing Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026